{"entity":{"id":"bbi-825","kind":"drug","name":"BBI-825","aka":[],"tldr":"BBI-825 is an oral small-molecule inhibitor from Boundless Bio that reached phase 1 for solid tumours with resistance gene amplifications; development has stopped.","summary":"BBI-825 is an oral small-molecule inhibitor from Boundless Bio. An oral selective inhibitor of ribonucleotide reductase; OnCo's text says it was meant to prevent ecDNA-mediated resistance (that wording is not re-verified here). Its furthest stage is phase 1, for solid tumours with resistance gene amplifications. ClinicalTrials.gov registers it in 2 studies linked below. STARMAP trial of BBI-825 wound down in 2025; POTENTIATE combination enrolment ceased (10-Q). Registry NCT06299761 TERMINATED. Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"Boundless Bio: sec.gov","url":"https://www.sec.gov/Archives/edgar/data/0001782303/000119312526339093/bold-20260630.htm"},{"label":"Boundless Bio: sec.gov","url":"https://www.sec.gov/Archives/edgar/data/0001782303/000119312526339093/bold-20260630.htm"},{"label":"Boundless Bio: clinicaltrials.gov","url":"https://clinicaltrials.gov/study/NCT06299761"},{"label":"ClinicalTrials.gov: trials of BBI-825","url":"https://clinicaltrials.gov/search?intr=BBI-825"}],"tags":["pipeline","ctgov-ingest","discontinued"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["boundless-bio"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06299761","nct05827614"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"BBI-825","modality":"Oral small-molecule inhibitor","mechanism":"An oral selective inhibitor of ribonucleotide reductase; OnCo's text says it was meant to prevent ecDNA-mediated resistance (that wording is not re-verified here).","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/bbi-825/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"boundless-bio","kind":"company","name":"Boundless Bio","route":"/companies/boundless-bio/"}],"trial":[{"id":"nct05827614","kind":"trial","name":"Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications","route":"/trials/nct05827614/"},{"id":"nct06299761","kind":"trial","name":"Study of the RNR Inhibitor BBI-825 in Subjects With Tumors With Resistance Gene Amplifications","route":"/trials/nct06299761/"}]}}